The European Medicines Agency (EMA, for its acronym in English) announced this Friday that it will decide on the authorization of the Oxford / Astra Zeneca vaccine “probably” at the end of this month. After receiving more information from the company, the EMA expects Astra Zeneca to submit an application for the conditional use license of its vaccine in the European Union next week.
Ten Reasons COVID-19 Vaccines Have Arrived So Quickly and Without Shortcuts
This would be the third vaccine approved by the EMA, after authorizing the one from Pfizer on December 21 and the one from Moderna last Wednesday. In UK It was already approved on December 30 and began to be administered on January 4.
The Oxford / AstraZeneca vaccine presents fewer logistical problems than those of Pfizer and Moderna. It is easier to store because it can be kept in a normal refrigerator, like the flu vaccine, while the one from Pfizer / BioNTech needs to be kept at -70ºC and the one from Moderna at -20ºC. Regarding its effectiveness, the data published at the beginning of December in the scientific journal The Lancet indicated that the vaccine is 62% effective when given two full doses of the vaccine, but that effectiveness amounts to 90% when half of the first dose is given followed by a full dose in the second.
The Oxford vaccine is also much cheaper than others that have shown efficacy. AstraZeneca’s goal is to sell the Oxford vaccine for € 2.50 / € 3.40 per injection, compared to € 17 for Pfizer and € 21 for Moderna.
AstraZeneca has reached agreements to manufacture 2 billion doses of your vaccine for next summer. Through the ‘Inclusive Europe Vaccine Alliance’, up to 400 million doses of Oxford vaccine will be supplied to European nations. As confirmed by the Minister of Health, Salvador Illa, Spain would have 31.5 million doses.